ONCOGENE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2021-11-03 1441036817

Stage Start Date
Editor in Chief Decision Complete 2nd Nov 21
Manuscript Decision complete 2nd Nov 21
Editor Decision Complete 2nd Nov 21
Under Consideration 1st Nov 21
Editor Assigned 30th Oct 21
Author Approved Converted Files 30th Oct 21
Submission 30th Oct 21

78 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2021-05-28 ruiruima

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤 ; Tumor
经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！

80 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-04-15 ms7000000598267418

oncogene 非OA版面费是多少呢？

60 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2020-08-07 1473f3c0m95(暂无昵称)

二审已经42天了，这正常么？

135 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2020-07-22 1473f3c0m95(暂无昵称)

请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了

151 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-10-11 14686542m84暂无昵称

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：tumor
经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？

71 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-07-02 1811e984f8m

偏重的研究方向：肿瘤
经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。

72 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2020-04-11 11718250

3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。

151 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2021-03-24 ms5000000012440598

有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21
Editor Review Completed 23rd Mar 21
Waiting for Potential Reviewer Assignment 3rd Mar 21
Monitoring Editor Assigned 3rd Mar 21
Potential Monitoring Editor Assigned 3rd Mar 21
Under Consideration 1st Mar 21
Editor Assigned 26th Feb 21
Author Approved Converted Files 26th Feb 21
Submission 26th Feb 21

124 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1066595, encodeId=1e201066595f3, content=Stage Start Date Editor in Chief Decision Complete 2nd Nov 21 Manuscript Decision complete 2nd Nov 21 Editor Decision Complete 2nd Nov 21 Under Consideration 1st Nov 21 Editor Assigned 30th Oct 21 Author Approved Converted Files 30th Oct 21 Submission 30th Oct 21 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f7c13068406, createdName=1441036817, createdTime=Wed Nov 03 14:08:19 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969299, encodeId=d78396929964, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 ; Tumor 经验分享：我的接收了，从5月6日投稿到5月24日接收，中间小修2次，超快！我最快的一次投稿！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Fri May 28 21:58:16 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211345, encodeId=d6ac12113459a, content=oncogene 非OA版面费是多少呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6265543620, createdName=ms7000000598267418, createdTime=Fri Apr 15 07:54:55 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806783, encodeId=9c26806e837c, content=二审已经42天了，这正常么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Fri Aug 07 13:45:30 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804014, encodeId=bf8c80401454, content=请问一下oncogene修回大概多久能有消息？我的已经all reviewers assigned 26天了，太着急了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70845201982, createdName=1473f3c0m95(暂无昵称), createdTime=Wed Jul 22 22:13:16 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093050, encodeId=794e20930500a, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：tumor 经验分享：我在oncogene上under review了两月了还没消息，有没有大神遇到这种情况，要不要写邮件问问的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226f5145607, createdName=14686542m84暂无昵称, createdTime=Tue Oct 11 08:27:58 CST 2022, time=2022-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230142, encodeId=615b1230142ba, content=偏重的研究方向：肿瘤 经验分享：老牌杂志，但近两年发表文章的质量良莠不齐，加上一定程度的扩刊，明年IF可能还会小幅度下降。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sat Jul 02 15:56:14 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588625, encodeId=d88458862521, content=3月14投稿，三天后也就是3月17，waiting for potential reviewer assignments ，4月11变成了editor review completed，然后直接EIC decision started。还没收到退稿信，但看大家的经验这是凉了，六月毕业，感觉好坑好委屈，既然不送审，为什么还要拖我整整一个月的时间呢？难道因为疫情原因编辑忘记拒稿了忘了整整三周半？想哭。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48b43066690, createdName=11718250, createdTime=Sat Apr 11 00:00:00 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950681, encodeId=733b95068132, content=有人遇到过这种情况吗？等待送审后是EIC决定。这是没送审还是系统里没更新其他通知EIC Decision Started 23rd Mar 21 Editor Review Completed 23rd Mar 21 Waiting for Potential Reviewer Assignment 3rd Mar 21 Monitoring Editor Assigned 3rd Mar 21 Potential Monitoring Editor Assigned 3rd Mar 21 Under Consideration 1st Mar 21 Editor Assigned 26th Feb 21 Author Approved Converted Files 26th Feb 21 Submission 26th Feb 21, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56895470045, createdName=ms5000000012440598, createdTime=Wed Mar 24 11:07:36 CST 2021, time=2021-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1237428, encodeId=ce40123e428d5, content=偏重的研究方向：cancer biology 经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02dc5450639, createdName=ms4000000217931705, createdTime=Mon Aug 08 19:15:52 CST 2022, time=2022-08-08, status=1, ipAttribution=)]

2022-08-08 ms4000000217931705

偏重的研究方向：cancer biology
经验分享：老牌期刊，运营差点劲。评基金尤其是肿瘤口还是很能打的，比molecular cancer认可度高。

57 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务